Anika Therapeutics Affirms FY2024 Sales Guidance Of $168M-$173M Vs, $170.84M Estimate
Portfolio Pulse from Benzinga Newsdesk
Anika Therapeutics has reaffirmed its fiscal year 2024 sales guidance, projecting revenues between $168 million and $173 million, which aligns closely with the $170.84 million estimate. The company expects growth in its Joint Preservation and Restoration segment, while its Non-Orthopedic segment is anticipated to decline.
August 08, 2024 | 9:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anika Therapeutics reaffirmed its FY2024 sales guidance of $168M-$173M, close to the $170.84M estimate. The company expects growth in Joint Preservation and Restoration, while Non-Orthopedic is anticipated to decline.
The reaffirmation of sales guidance close to the market estimate is likely to be viewed positively by investors, especially with expected growth in key segments like Joint Preservation and Restoration. However, the decline in the Non-Orthopedic segment may temper some of the enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100